一项评估他莫昔芬治疗胰腺腺癌的II期研究。
A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma.
作者信息
Crowson M C, Dorrell A, Rolfe E B, Fielding J W
出版信息
Eur J Surg Oncol. 1986 Dec;12(4):335-6.
PMID:3780986
Abstract
Oestrogen receptors have been demonstrated in pancreatic adenocarcinoma and it has been suggested that tamoxifen increases patient survival. This study of 14 patients with unresectable carcinoma of the pancreas fails to demonstrate any objective response from endocrine manipulation using tamoxifen.
摘要
在胰腺腺癌中已证实存在雌激素受体，并且有人提出他莫昔芬可提高患者生存率。这项针对14例无法切除的胰腺癌患者的研究未能证明使用他莫昔芬进行内分泌治疗有任何客观反应。
Zotero 插件